TP-110

CAT: 0804-HY-118522Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-118522Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc[1][2].
CAS Number
[688737-95-3]
UNSPSC
12352005
Target
Apoptosis; Caspase; IAP; NF-κB; PARP; Proteasome
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CC([C@@H](C(N)=O)N(C([C@H](CC1=CC=C(C=C1)OC)NC(CC2=C3C=CC=CC3=CC=C2)=O)=O)C(CC4=CC=C(C=C4)OC)C=O)C
Molecular Formula
C37H41N3O6
Molecular Weight
623.74
References & Citations
[1]Iijima M, Momose I, Ikeda D. TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells. Anticancer Res. 2009 Apr;29 (4) :977-85.|[2]Momose I, et al. A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells. Biosci Biotechnol Biochem. 2007 Apr;71 (4) :1036-43.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3; Caspase 8; Caspase 9; cIAP-1; NF-κB; PARP; XIAP

Popular Products